Cardiff Oncology Gestione
Gestione criteri di controllo 3/4
Cardiff Oncology Il CEO è Mark Erlander, nominato in May2020, e ha un mandato di 4.5 anni. la retribuzione annua totale è $ 1.55M, composta da 38.4% di stipendio e 61.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.048% delle azioni della società, per un valore di $ 59.98K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 10.2 anni.
Informazioni chiave
Mark Erlander
Amministratore delegato
US$1.5m
Compenso totale
| Percentuale dello stipendio del CEO | 38.4% |
| Mandato del CEO | 4.5yrs |
| Proprietà del CEO | 0.05% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 10.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$2m | US$594k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$2m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
Compensazione vs Mercato: La retribuzione totale di Mark ($USD 1.55M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.07K ).
Compensazione vs guadagni: La retribuzione di Mark è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Mark Erlander (64 yo)
4.5yrs
Mandato
US$1,547,772
Compensazione
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$1.55m | 0.048% $ 60.0k | |
| Chief Financial Officer | 3.3yrs | US$917.72k | 0.12% $ 147.0k | |
| Chief Medical Officer | 1.8yrs | US$1.26m | 0% $ 0 | |
| Chief Scientific Officer | 2.8yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 9.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Finance | 1.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | Nessun dato | Nessun dato |
2.8yrs
Durata media
61.5yo
Età media
Gestione esperta: Il team dirigenziale di CRDF è considerato esperto (durata media dell'incarico 2.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$1.55m | 0.048% $ 60.0k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.6yrs | US$114.43k | 1.36% $ 1.7m | |
| Member of Scientific Advisory Board | 10.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 12yrs | US$35.85k | Nessun dato | |
| Independent Chairman of the Board | 10.8yrs | US$154.43k | 0.061% $ 76.1k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 14.6yrs | Nessun dato | Nessun dato | |
| Independent Director | 4.6yrs | US$116.43k | 0.22% $ 278.8k | |
| Member of Scientific Advisory Board | 10.2yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.4yrs | US$110.43k | 0.020% $ 24.5k | |
| Member of Scientific Advisory Board | 14.6yrs | Nessun dato | Nessun dato |
10.2yrs
Durata media
72yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di CRDF è composto da personale esperto e esperto (durata media dell'incarico 10.2 anni).